在心力衰竭中心室节律失常的管理:更少可以更好吗?
1Thomas Jefferson University Hospital, 111 S. 11th Street, Philadelphia, PA, 19146, USA. Eitan.Frankel@Jefferson.edu.
Current cardiology reports
|July 30, 2024
概括
对心室失常症 (VAs) 需要新的治疗方法,因为抗失常药物和导管切除 (CA) 有限制. 较少的侵入性选择,包括自主神经系统向和立体辐射,显示出对管理VA的承诺.
科学领域:
- 心脏病学 心脏病学
- 电力生理学 电力生理学
- 医疗技术 医疗技术 医学技术
背景情况:
- 心室失常 (Vas) 是心力衰竭患者发病和死亡的重要原因.
- 目前的治疗方法,如抗失律药物和导管切除 (CA) 有局限性,需要替代疗法.
研究的目的:
- 审查最近的进展和心室节律失常的替代治疗策略.
- 探索VA的急性和慢性管理的选择.
主要方法:
- 审查当前关于风险分层,废弃技术和新兴治疗方法的文献.
- 讨论急性情形 (例如,心室动脉冲动电风暴) 和慢性情形中的患者管理.
主要成果:
- 风险分层和废弃技术的进步可能会减轻CA并发症.
- 包括自主神经系统调制和立体性身体辐射疗法 (SBRT) 在内的更少侵入性疗法正在作为替代方案出现.
- 机械循环支持 (MCS) 可能是必要的高风险患者接受CA.
结论:
- 针对VA的个性化治疗需要进一步的研究.
- 较少侵入性的方法为VA管理提供了潜在的替代策略.
- 多学科护理对于管理复杂的VA病例至关重要,特别是在急性情况下.
相关概念视频
Disturbances in Heart Rhythm
927
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
927
Mechanism of Cardiac Arrhythmias
909
Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.
909
Heart Failure Drugs: β-Blockers
332
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
332
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413
Heart Failure Drugs: Inotropic Agents
555
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
555
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
727
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
727


